Metabolic Control in Patients with Type 2 Diabetes Using Humalog® Mix50™ Injected Three Times Daily: Crossover Comparison with Human Insulin 30/70

Abstract

Objective: Patients with type 2 diabetes most frequently use injections of premixed insulin formulations twice daily, but intensified insulin therapy may provide better control. This study was designed to compare metabolic control with three daily injections of Humalog Mix50 or premixed human insulin 30/70 (30 % regular/70 % NPH) twice daily in accordance with normal prescription practice. Research Design and Methods: The study cohort of 40 patients with type 2 diabetes used a two-way, crossover design. Patients were randomized to either Mix50 at each main meal or human insulin 30/70 at breakfast and dinner for 3 months, followed by the alternate treatment for 3 months. Blood glucose was measured by the patients at baseline and at the end of each treatment sequence. No significant carryover effects were observed, so treatment sequences were combined and data analyzed by unpaired t-tests. Results: Mean blood glucose level was significantly (p = 0.010) decreased with Mix50 but not with 30/70 (p = 0.237), and there was a significant difference between treatments at the endpoint (p = 0.035). Fasting blood glucose was increased pre-breakfast and decreased at bedtime with Mix50 but was not significantly changed pre-lunch or dinner or at any time with 30/70 insulin. Blood glucose excursions were significantly decreased with Mix50 after breakfast (p = 0.002), lunch (p < 0.001) and dinner (p = 0.037) but not significantly changed from baseline with 30/70 insulin. The decrease from baseline in HbA_1c was significantly (p = 0.021) greater with Mix50 than with 30/70 insulin. There were no significant differences between treatments regarding incidence of hypoglycemia or adverse events. Conclusions: In patients with type 2 diabetes, a regimen of Humalog Mix50 administered three times daily before meals maintains glucose control more effectively than premixed human insulin 30/70 administered before breakfast and dinner.

Type 2 diabetes - diabetes control - Humalog Mix50 - postprandial glucose

References

• 1 Berne C, Eriksson G, Lundgren P. How accurate are insulin mixtures prepared by the patient.  Diabetes Care. 1986;  9 23-26
• 2 Bell D S, Clements R S, Perentesis G, Roddam R, Wagenknecht L. Dosage accuracy of self-mixed versus premixed insulin.  Arch Intern Med. 1991;  151 2265-2269
• 3 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furoyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic macrovascular complications in Japanese patients with non-insulin-dependent diabetes mellitus. A randomized prospective 6-year study.  Diab Res Clin Pract. 1995;  28 103 117
• 4 UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-854
• 5 Howey D C, Bowsher R R, Brunelle R L, Rowe H M, Santa P F, Dowing-Shelton J, Woodworth J R. [Lys(B28)Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin.  Diabetes. 1994;  43 396-402
• 6 Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodworth J, Gudat U, Heinemann L. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.  Diabetes Care. 1998;  21 800-803
• 7 Roach P, Trautmann M, Arora V, Sun B, Anderson J H. and the Mix 50 Study Group . Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix 25 and insulin lispro Mix 50.  Clin Therapeutics. 1999;  21 523-534
• 8 Wojcicki J M. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull ”M”-value.  Horm Metab Res. 1995;  27 1-5
• 9 Koch G G. The use of non-parametric methods in statistical analysis of the two period change-over design.  Biometrics. 1972;  28 577-584
• 10 Taulbee J D. A note on the use of nonparametric methods in the statistical analysis of the two-period changeover design.  Biometrics. 1982;  38 1053-55
• 11 Taylor R, Davies R, Fox C, Sampson M, Weaver J U, Wood L. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study.  Diabetes Care. 2000;  23 1612-1618
• 12 Hanefeld M, Temelkova-Kurktschiev T. Control of post-prandial hyperglycemia - an essential part of good diabetes treatment and prevention of cardiovascular complications.  Nutr Metab Cardiovasc Dis. 2002;  12 98-107
• 13 Ceriello A. Mechanisms of tissue damage in the postprandial state.  Int J Clin Pract Suppl. 2001;  123 7-12
• 14 Alberti G. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1998 - 1999 International Diabetes Federation European Region.  Exp Clin Endocrinol Diabetes. 1999;  107 390-420
• 15 Turner H E, Matthews D R. The use of fixed-mixture insulin in clinical practice.  Eur J Clin Pharmacol. 2000;  56 19-25
• 16 Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, Brunetti P, Bolli G B. Use of the short acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of replacement of basal insulin and time-interval injection-meal.  Diabet Med. 1998;  15 592-600
• 17 Bastyr E J III., Stuart C A, Brodows R G, Schwartz S, Graf C J, Zagar A, Robertson K E. for the IOEZ Study Group . Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA_1c.  Diabetes Care. 2000;  23 1236-1241
• 18 Anderson J H, Brunelle R L, Koivisto V A, Trautmann M E, Vignati L, DiMarchi R. and the Multicenter Insulin Lispro Study Group . Improved mealtime treatment of diabetes mellitus using insulin analogue.  Clin Ther. 1997;  19 62-72